India · Delayed Price · Currency is INR Aarti Drugs Statistics
Total Valuation
Aarti Drugs has a market cap or net worth of INR 34.03 billion. The enterprise value is 39.55 billion.
| Market Cap | 34.03B |
| Enterprise Value | 39.55B |
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | Feb 9, 2026 |
Share Statistics
Aarti Drugs has 91.27 million shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 91.27M |
| Shares Outstanding | 91.27M |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 47.31% |
| Owned by Institutions (%) | 19.16% |
| Float | 35.37M |
Valuation Ratios
The trailing PE ratio is 17.45 and the forward PE ratio is 16.64. Aarti Drugs's PEG ratio is 0.72.
| PE Ratio | 17.45 |
| Forward PE | 16.64 |
| PS Ratio | 1.33 |
| PB Ratio | 2.20 |
| P/TBV Ratio | 2.22 |
| P/FCF Ratio | 42.42 |
| P/OCF Ratio | 13.42 |
| PEG Ratio | 0.72 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.69, with an EV/FCF ratio of 49.31.
| EV / Earnings | 20.29 |
| EV / Sales | 1.54 |
| EV / EBITDA | 12.69 |
| EV / EBIT | 16.17 |
| EV / FCF | 49.31 |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.59 |
| Quick Ratio | 0.93 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.85 |
| Debt / FCF | 7.19 |
| Interest Coverage | 7.26 |
Financial Efficiency
Return on equity (ROE) is 13.36% and return on invested capital (ROIC) is 10.98%.
| Return on Equity (ROE) | 13.36% |
| Return on Assets (ROA) | 5.67% |
| Return on Invested Capital (ROIC) | 10.98% |
| Return on Capital Employed (ROCE) | 12.92% |
| Weighted Average Cost of Capital (WACC) | 6.09% |
| Revenue Per Employee | 19.98M |
| Profits Per Employee | 1.52M |
| Employee Count | 1,284 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 3.36 |
Taxes
In the past 12 months, Aarti Drugs has paid 159.70 million in taxes.
| Income Tax | 159.70M |
| Effective Tax Rate | 7.57% |
Stock Price Statistics
The stock price has decreased by -21.17% in the last 52 weeks. The beta is 0.35, so Aarti Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -21.17% |
| 50-Day Moving Average | 371.86 |
| 200-Day Moving Average | 415.32 |
| Relative Strength Index (RSI) | 44.04 |
| Average Volume (20 Days) | 7,088 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aarti Drugs had revenue of INR 25.65 billion and earned 1.95 billion in profits. Earnings per share was 21.36.
| Revenue | 25.65B |
| Gross Profit | 9.47B |
| Operating Income | 2.45B |
| Pretax Income | 2.11B |
| Net Income | 1.95B |
| EBITDA | 3.12B |
| EBIT | 2.45B |
| Earnings Per Share (EPS) | 21.36 |
Balance Sheet
The company has 242.80 million in cash and 5.77 billion in debt, with a net cash position of -5.52 billion or -60.52 per share.
| Cash & Cash Equivalents | 242.80M |
| Total Debt | 5.77B |
| Net Cash | -5.52B |
| Net Cash Per Share | -60.52 |
| Equity (Book Value) | 15.49B |
| Book Value Per Share | 169.79 |
| Working Capital | 5.46B |
Cash Flow
In the last 12 months, operating cash flow was 2.54 billion and capital expenditures -1.73 billion, giving a free cash flow of 802.20 million.
| Operating Cash Flow | 2.54B |
| Capital Expenditures | -1.73B |
| Depreciation & Amortization | 669.70M |
| Net Borrowing | -269.80M |
| Free Cash Flow | 802.20M |
| FCF Per Share | 8.79 |
Margins
Gross margin is 36.90%, with operating and profit margins of 9.54% and 7.60%.
| Gross Margin | 36.90% |
| Operating Margin | 9.54% |
| Pretax Margin | 8.22% |
| Profit Margin | 7.60% |
| EBITDA Margin | 12.15% |
| EBIT Margin | 9.54% |
| FCF Margin | 3.13% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 0.54%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 0.54% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 9.32% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 0.55% |
| Earnings Yield | 5.73% |
| FCF Yield | 2.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 30, 2020. It was a forward split with a ratio of 4.
| Last Split Date | Sep 30, 2020 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |